Free  The EMA is withholding too much information

Marketing Authorisations

Ozanimod (Zeposia°) in multiple sclerosis

Nintedanib (Ofev°) in various types of pulmonary fibrosis

Fostemsavir (Rukobia°) in multidrug-resistant HIV-1 infection

Inset. Pharmacological classes of the main antiretroviral drugs on the European market as of 16 December 2021

Apremilast (Otezla°) for oral aphthous ulcers associated with Behçet's disease

Free  Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer

Ipilimumab (Yervoy°) and nivolumab (Opdivo°), in combination with other cytotoxic drugs, as first-line treatment for certain lung cancers

Casirivimab + imdevimab (Ronapreve°) in early covid-19

Molnupiravir (Lagevrio°) in early covid-19

Budesonide + formoterol + glycopyrronium (Trixeo Aerosphere°) in COPD

Conestat alfa (Ruconest°) in hereditary angioedema from 2 years of age

Guselkumab (Tremfya°) in psoriatic arthritis

Adverse Effects

Pharmacobezoars may prolong effects of overdose (continued)

Terbinafine: severe mucosal and skin damage

Rivaroxaban + amiodarone: gastrointestinal haemorrhage

Outlook

Free  European Medicines Agency: transparency policy marred by too many failings

Inset. The European Medicines Agency's "proactive" transparency: embracing transparency or avoiding litigation?

Masthead

Free  Masthead